Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CAPS Rating: 4 out of 5

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.


Player Avatar pchop123 (80.45) Submitted: 10/19/2011 1:36:33 PM : Outperform Start Price: $6.27 NBIX Score: +14.87

way oversold for the promising potential here

Featured Broker Partners